Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia
- 1 Downloads
Incretins are hormones with a wide range of biological activity. We studied the ratio of the glycemic effect of the glucagon-like peptide-1 mimetic and its effect on the renal excretion of sodium and water. It was found that both effects depend on the initial blood concentration of glucose. In normoglycemia, exenatide had no effect on blood sugar level, but it significantly increased urinary sodium excretion and reabsorption of solute-free water. In hyperglycemia the blood glucose concentration was normalized by exenatide, while the excretion of sodium by the kidneys and the reabsorption of solute-free water were increased to a small extent. This pattern was found both in patients with type 2 diabetes mellitus and in rats with hyperglycemia induced by intraperitoneal injection of glucose.
Keywords:hyperglycemia glucagon-like peptide-1 sodium solute-free water kidney diabetes mellitus exenatide
This study was carried out in the framework of the state contract of the Federal Agency for Scientific Organizations of Russia (state registration no. АААА-А18-118012290371-3) and supported in part by the Russian Foundation for Fundamental Research, project no. 17-04-01216.
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of interests. The authors declare that they have no conflict of interest connected with the publication of this article.
Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies involving human participants were in accordance with the biomedical ethics principles formulated in the 1964 Helsinki Declaration and its later amendments and approved by the bioethics commission of the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences (St. Petersburg). Informed consent was obtained from all individual participants involved in the study after their being explained the potential risks and advantages, as well as the essence of the future study.
- 1.Shestakova, M.V. and Vikulova, O.K., Modern pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1), Sakharnyi Diabet, 2007, no. 1, p. 9.Google Scholar
- 3.Galstyan, G.R., Karataeva, E.A., and Yudovich, E.A., Evolution of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, Sakharnyi Diabet, 2017, vol. 20, no. 4, p. 286.Google Scholar
- 4.Biryukova, E.V. and Yakubova, T.R., Byetta: past, present, and future, Eff. Farmakoter., 2015, no. 11, p. 34.Google Scholar
- 9.Kutina, A.V., Golosova, D.V., Marina, A.S., et al., Role of Vasopressin in the regulation of renal sodium excretion: interaction with glucagon-like peptide-1, J. Neuroendocrinol., 2016, vol. 28, no. 4. https://doi.org/10.1111/jne.12367
- 14.Tonneijck, L., Smits, M.M., Muskiet, M.H., et al., Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 2016, vol. 39, no. 11, p. 2042.CrossRefGoogle Scholar